Doc2Doc
OperatingDoc2Doc, Inc./DE
Retail & Consumer · Atlanta, GA
Doc2Doc Lending has provided over $136 million in loans to more than 3,500 physicians, enabling them to overcome financial barriers and focus on patient care. We believe we can achieve 30% year-over-year growth* based on current trends and our strategic partnerships, aiming to redefine financial solutions for the healthcare community.
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines, and each class is drawn as its own line.
Cap table
Share counts as of May 6, 2026| Class | Outstanding | Votes / share | Share of total | Liquidation | Last price |
|---|---|---|---|---|---|
| Series Seed Preferred Stockpreferred | 2,580,138 | 1 | 73.6% | 1× | $1.71Mar 2023 |
| Common Stock(as of Dec 31, 2025) | 927,560 | — | 26.4% | — | — |
| Total | 3,507,698 | 100% |
Shares outstanding over timein today's share terms
Principal holders% as the filing states it, May 6, 2026
- Zwade Marshall6,166,000 Class A Voting Common Stock22.4%of Class A Voting
Sold to the crowd
- Reg CF · Feb 2025611,711 Class B Non-Voting Common Stock at $1.82$1.1M· 283 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
9 people
Dr. Marshall is an Emory and Harvard-trained, double-board certified anesthesiologist and interventional pain management specialist. He is the Chief Medical Officer of Regenerative Spine and Pain Specialists. Dr. Marshall attended Emory University, where he completed a bachelor’s degree in Economics and simultaneously completed his pre-medicine coursework. In addition to working 40-45 hours per week on Doc2Doc, Dr. Marshall also works 26-30 hours per week as Chief Medical Officer for Regenerative Spine & Pain Specialists.
Chris Cronk is the Chief Financial Officer of Doc2Doc, Inc., manages all aspects of finance and accounting and is intimately involved in company strategy and planning. He previously spent 22 years working for Bank of America Merrill Lynch and its predecessor companies doing fixed income investment banking and advisory work for finance companies.
Katie Miller has over 20+ years of experience in financial services, specializing in product development and marketing. In leadership roles at GE Capital, Citibank, and Synchrony, she has launched innovative products, expanded markets, and driven portfolio growth. Her expertise lies in developing and executing strategic initiatives that drive portfolio growth and deliver measurable business outcomes.
For 25 years Dr. Darin Vercillo has been a practicing physician and healthcare technology executive. His passion is to grow markets and solutions in the healthcare space and ensure they succeed. As a CEO, CMO, and director for technology companies and provider organizations, he has combined expertise as an internal medicine physician, hospital and medical director, business executive, and product strategist to build relationships and bridge gaps in a rapidly growing industry. Dr. Vercillo's experience includes leadership, strategy, and operations with startup, growth stage, and at-scale entities as well as funding and M&A activities.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGAR- Form C-ARMay 6, 20260002051563-26-000004EDGAR
- Form C-UJul 25, 20250001665160-25-001323EDGAR
- Form C/AJul 8, 20250001665160-25-001276EDGAR
- Form C/AMay 21, 20250001665160-25-001129EDGAR
- Form C-ARMay 1, 20250001665160-25-000903EDGAR
- Form C/AApr 30, 20250001665160-25-000902EDGAR
- Form C/AFeb 27, 20250001665160-25-000330EDGAR
- Form C-UFeb 11, 20250001665160-25-000235EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.